DSIP (Delta Sleep-Inducing Peptide)
Delta Sleep-Inducing Peptide | Sleep & Stress Modulator
Community Research
Join others researching DSIP — share findings, ask questions, and learn from real experiences
DSIP is a naturally occurring nonapeptide discovered in 1974 in rabbit brain. Originally isolated for sleep-promoting properties, it has diverse neuromodulatory effects including stress reduction, pain modulation, and endocrine regulation without traditional sedative effects.
Modulates multiple neurotransmitter systems including GABA enhancement, NMDA receptor interaction, and endogenous opioid system modulation. Also regulates hypothalamic-pituitary-adrenal axis for stress response.
Molecular Data
WAGGDASGETryptophan
Position 1
Alanine
Position 2
Glycine
Position 3
Glycine
Position 4
Aspartic Acid
Position 5
Alanine
Position 6
Serine
Position 7
Glycine
Position 8
Glutamic Acid
Position 9
Research Indications
Promotes delta wave sleep, the most restorative sleep phase for physical recovery.
Reduces sleep latency and nocturnal awakenings without morning grogginess.
Supports natural sleep cycles rather than forcing sedation like traditional sleep aids.
Helps regulate cortisol and stress response through HPA axis modulation.
Supports emotional balance without sedation.
May help reduce anxiety through neuromodulatory effects.
Significantly reduced pain levels in 6 of 7 patients with chronic pain conditions.
Helps manage withdrawal symptoms in alcohol and opioid-dependent patients.
Supports post-training recovery through enhanced sleep quality.
Dosing Protocols
Subcutaneous injection is the standard route. Best taken 30-60 minutes before bedtime. Some prefer earlier evening dosing for gradual onset.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Sleep enhancement | 100-200mcg | Once nightly | SubQ |
| Chronic pain support | 250-300mcg | Daily | SubQ or IV |
| Stress management | 150mcg | Evening | SubQ |
| Withdrawal support | 200-300mcg | Twice daily | IV preferred |
| Athletic recovery | 100-150mcg | Post-training | SubQ |
Reconstitution Instructions
- DSIP peptide vial (1-5mg typical)
- Bacteriostatic water (1-2mL)
- Insulin syringes (0.3-0.5mL)
- Alcohol swabs
- Sterile needle for mixing
- 1 Clean vial tops with alcohol swab and let dry completely
- 2 For 1mg vial, add 1mL bacteriostatic water (creates 1000mcg/mL)
- 3 Inject water slowly down vial side to prevent foaming
- 4 Gently roll between palms - do not shake
- 5 Solution should be clear and colorless
- 6 For 100mcg dose, draw 0.1mL (10 units on insulin syringe)
- 7 Store reconstituted peptide in refrigerator immediately
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated with minimal side effects
- Mild drowsiness or dizziness initially (some users)
- Occasional headaches in sensitive individuals
- No tolerance or dependence reported in studies
Stop Signs - Discontinue if:
- Excessive daytime sedation
- Paradoxical insomnia or agitation
- Persistent headaches
- Any allergic reactions
- Mood changes or depression
- Unusual dreams causing distress
Contraindications
- Avoid driving until effects are known
- Pregnancy or breastfeeding
Quality Checklist
Good Signs
- White lyophilized powder before reconstitution
- Clear and colorless solution when properly mixed
- Reputable source with third-party testing
Warning Signs
- Short stability period - use within 14 days when reconstituted
- Protect from light exposure and temperature fluctuations
- Limited nasal formulation stability (use within 10 days)
Bad Signs
- Yellow or cloudy solution indicates degradation or contamination
- Discolored powder
References
- Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind StudySchneider-Helmert DNeuropsychobiology (1992)
Double-blind placebo-controlled study; DSIP (15-30 nmol for 6 consecutive nights) showed higher sleep efficiency and shorter sleep latency, though statistical effects were weak.
- Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes: A Clinical Pilot StudySchoenenberger GA, Schneider-Helmert DEuropean Neurology (1984)
7 patients with chronic pain (migraine, vasomotor headaches); 25 nmol IV DSIP for 10 days significantly reduced pain levels in 6 of 7 patients.
- DSIP in the Treatment of Withdrawal Syndromes from Alcohol and OpiatesDick P, Costa C, Fayolle K, et al.European Neurology (1984)
107 patients (47 alcohol, 60 opiate withdrawal); DSIP (25 nmol/kg IV) produced beneficial effects in 97% of opiate addicts and 87% of alcoholics with immediate onset and lasting symptom relief.
- Acute and Delayed Effects of DSIP (Delta Sleep-Inducing Peptide) on Human Sleep BehaviorSchneider-Helmert D, Schoenenberger GAInternational Journal of Peptide and Protein Research (1983)
6 normal volunteers; 25 nmol/kg IV DSIP induced 59% increase in total sleep time within 130 minutes; improved subsequent night sleep efficiency without sedation.
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats After Focal StrokeTukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al.Pharmaceutics (2021)
120 mcg/kg intranasal DSIP for 8 days accelerated motor function recovery (rotarod test) after focal stroke in rats; brain infarction was smaller but not statistically significant.
- Successful Treatment of Withdrawal Symptoms with Delta Sleep-Inducing PeptideLarbig W, Gerber WD, Kluck M, Schoenenberger GANeuropsychobiology (1984)
DSIP (25 nmol/kg IV) administered to 67 patients; beneficial effect in 48 of 49 evaluable patients (22 alcoholics and 26 of 27 opiate addicts) with good tolerance.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.